



Supplementary material

Supplementary Figure 1: The FluidCrystal® drug delivery system¹⁻⁵

CAM2029 pre-filled pen
(autoinjector)




Supplementary Figure 2: Patient disposition



*Discontinued treatment and withdrawn from trial because of withdrawal of consent (n=5); †AE: injection site hemorrhage, Grade 1 (n=1); depression, Grade 1 (n=1). AE, adverse event; SD, standard deviation; SoC, standard of care.

Supplementary Figure 3: Overview of AIS



ACROINNOVA 2 was not powered to assess changes in acromegaly symptom severity using the AIS.

*In ACROINNOVA 2, paraesthesia was included in addition to the five symptoms assessed with the AIS in Fleseriu *et al.* 2020.^{5,7}

References

1. Tiberg F *et al.* *Chem Lett* 2012;41:1090–2.
2. Tiberg F, Johnsson M. *J Drug Deliv Science Tech* 2011;21:101–9.
3. Engstedt J *et al.* *Colloids Surf B Biointerfaces* 2024;239:113955.
4. Tiberg F *et al.* *Br J Clin Pharmacol* 2015;80:460–72.
5. Ferone D *et al.* *J Clin Endocrinol Metab* 2025;110:1729–39.
6. Camurus AB. Oczyesa® (CAM2029). UK Summary of Product Characteristics, 2025.
7. Fleseriu M *et al.* *Pituitary* 2020;23:347–58.
8. Fleseriu M *et al.* *Front Endocrinol* 2021;12:627711.